Your browser doesn't support javascript.
loading
Established and emerging GABAA receptor pharmacotherapy for epilepsy.
Richardson, Robert J; Petrou, Steven; Bryson, Alexander.
Affiliation
  • Richardson RJ; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia.
  • Petrou S; Department of Neurology, Austin Health, Heidelberg, VIC, Australia.
  • Bryson A; Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia.
Front Pharmacol ; 15: 1341472, 2024.
Article in En | MEDLINE | ID: mdl-38449810
ABSTRACT
Drugs that modulate the GABAA receptor are widely used in clinical practice for both the long-term management of epilepsy and emergency seizure control. In addition to older medications that have well-defined roles for the treatment of epilepsy, recent discoveries into the structure and function of the GABAA receptor have led to the development of newer compounds designed to maximise therapeutic benefit whilst minimising adverse effects, and whose position within the epilepsy pharmacologic armamentarium is still emerging. Drugs that modulate the GABAA receptor will remain a cornerstone of epilepsy management for the foreseeable future and, in this article, we provide an overview of the mechanisms and clinical efficacy of both established and emerging pharmacotherapies.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article Affiliation country: Australia